Innoviva (INVA) Other Accumulated Expenses (2010 - 2024)
Innoviva posted quarterly Other Accumulated Expenses of $17.1 million for Q2 2024, down 23.86% year-on-year from $22.5 million in Q3 2023, and down 27.85% on a QoQ basis from $23.7 million in Q1 2024.
Innoviva (INVA) has 15 years of Other Accumulated Expenses data on file, last reported at $17.1 million in Q2 2024.
- For the quarter ending Q2 2024, Other Accumulated Expenses fell 23.86% year-over-year to $17.1 million; the trailing twelve-month figure through Jun 2024 stood at $17.1 million (down 23.86% YoY), and the FY2023 full-year result was $19.7 million, down 7.12% from the prior year.
- Other Accumulated Expenses for Q2 2024 stood at $17.1 million, down from $23.7 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $24.9 million in Q1 2023 and bottomed at $734000.0 in Q1 2020.
- The 5-year median for Other Accumulated Expenses is $11.6 million (2022), against an average of $11.3 million.
- The widest annual swing landed in 2020, when Other Accumulated Expenses tumbled 44.01%; it then jumped 2043.0% in 2022.
- A 5-year view of Other Accumulated Expenses shows it stood at $1.4 million in 2020, then decreased by 28.03% to $1.0 million in 2021, then surged by 2001.78% to $21.2 million in 2022, then dropped by 7.12% to $19.7 million in 2023, then retreated by 13.02% to $17.1 million in 2024.
- The last three Other Accumulated Expenses figures came in at $17.1 million (Q2 2024), $23.7 million (Q1 2024), and $19.7 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 17.13 Mn |
| Mar 31, 2024 | 23.75 Mn |
| Dec 31, 2023 | 19.70 Mn |
| Sep 30, 2023 | 24.70 Mn |
| Jun 30, 2023 | 22.50 Mn |
| Mar 31, 2023 | 24.90 Mn |
| Dec 31, 2022 | 21.21 Mn |
| Sep 30, 2022 | 15.12 Mn |
| Jun 30, 2022 | 17.14 Mn |
| Mar 31, 2022 | 8.07 Mn |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 880,000.00 |
| Jun 30, 2021 | 800,000.00 |
| Mar 31, 2021 | 1.47 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Sep 30, 2020 | 1.22 Mn |
| Jun 30, 2020 | 776,000.00 |
| Mar 31, 2020 | 734,000.00 |
| Dec 31, 2019 | 562,000.00 |
| Sep 30, 2019 | 1.01 Mn |
| Jun 30, 2019 | 1.39 Mn |
| Mar 31, 2019 | 1.26 Mn |
| Dec 31, 2018 | 955,000.00 |
| Sep 30, 2018 | 865,000.00 |
| Jun 30, 2018 | 909,000.00 |
| Mar 31, 2018 | 918,000.00 |
| Dec 31, 2017 | 1.50 Mn |
| Sep 30, 2017 | 1.16 Mn |
| Jun 30, 2017 | 2.46 Mn |
| Mar 31, 2017 | 3.18 Mn |
| Dec 31, 2016 | 1.10 Mn |
| Sep 30, 2016 | 1.73 Mn |
| Jun 30, 2016 | 1.39 Mn |
| Mar 31, 2016 | 1.69 Mn |
| Dec 31, 2015 | 2.22 Mn |
| Sep 30, 2015 | 2.46 Mn |
| Jun 30, 2015 | 1.79 Mn |
| Mar 31, 2015 | 1.69 Mn |
| Dec 31, 2014 | 2.11 Mn |
| Mar 31, 2014 | 9.89 Mn |
| Dec 31, 2013 | 9.71 Mn |
| Sep 30, 2013 | 3.09 Mn |
| Jun 30, 2013 | 9.22 Mn |
| Mar 31, 2013 | 6.05 Mn |
| Dec 31, 2012 | 6.55 Mn |
| Sep 30, 2012 | 1.84 Mn |
| Jun 30, 2012 | 4.90 Mn |
| Mar 31, 2012 | 6.55 Mn |
| Dec 31, 2011 | 6.96 Mn |
| Sep 30, 2011 | 5.08 Mn |
| Jun 30, 2011 | 1.94 Mn |
| Dec 31, 2010 | 2.01 Mn |